Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

1.

Markov's modeling for screening strategies for colorectal cancer.

Barouni M, Larizadeh MH, Sabermahani A, Ghaderi H.

Asian Pac J Cancer Prev. 2012;13(10):5125-9.

2.

The economic evaluation of screening for colorectal cancer: Case of Iran.

Barouni M, Ghaderi H, Shahmoradi MK.

Clin Lab. 2013;59(5-6):667-74.

PMID:
23865368
3.

The cost-effectiveness of screening for colorectal cancer.

Telford JJ, Levy AR, Sambrook JC, Zou D, Enns RA.

CMAJ. 2010 Sep 7;182(12):1307-13. doi: 10.1503/cmaj.090845. Epub 2010 Jul 12.

4.

Cost-effectiveness of colonoscopy in screening for colorectal cancer.

Sonnenberg A, Delcò F, Inadomi JM.

Ann Intern Med. 2000 Oct 17;133(8):573-84.

PMID:
11033584
5.

Comparative effectiveness and cost-effectiveness of screening colonoscopy vs. sigmoidoscopy and alternative strategies.

Sharaf RN, Ladabaum U.

Am J Gastroenterol. 2013 Jan;108(1):120-32. doi: 10.1038/ajg.2012.380. Epub 2012 Dec 18.

PMID:
23247579
6.

Cost-effectiveness of screening for colorectal cancer in the general population.

Frazier AL, Colditz GA, Fuchs CS, Kuntz KM.

JAMA. 2000 Oct 18;284(15):1954-61.

PMID:
11035892
7.

Cost effectiveness and projected national impact of colorectal cancer screening in France.

Hassan C, Benamouzig R, Spada C, Ponchon T, Zullo A, Saurin JC, Costamagna G.

Endoscopy. 2011 Sep;43(9):780-93. doi: 10.1055/s-0030-1256409. Epub 2011 May 27.

PMID:
21623557
8.

Cost-effectiveness analysis of colorectal cancer screening with stool DNA testing in intermediate-incidence countries.

Wu GH, Wang YM, Yen AM, Wong JM, Lai HC, Warwick J, Chen TH.

BMC Cancer. 2006 May 24;6:136.

9.

Cost-effectiveness modeling of colorectal cancer: computed tomography colonography vs colonoscopy or fecal occult blood tests.

Lucidarme O, Cadi M, Berger G, Taieb J, Poynard T, Grenier P, Beresniak A.

Eur J Radiol. 2012 Jul;81(7):1413-9. doi: 10.1016/j.ejrad.2011.03.027. Epub 2011 Mar 27.

PMID:
21444171
10.

Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer.

Dinh T, Ladabaum U, Alperin P, Caldwell C, Smith R, Levin TR.

Clin Gastroenterol Hepatol. 2013 Sep;11(9):1158-66. doi: 10.1016/j.cgh.2013.03.013. Epub 2013 Mar 28.

PMID:
23542330
11.
12.
13.

What is the most cost-effective population-based cancer screening program for Chinese women?

Woo PP, Kim JJ, Leung GM.

J Clin Oncol. 2007 Feb 20;25(6):617-24.

15.

Fecal occult blood testing when colonoscopy capacity is limited.

Wilschut JA, Habbema JD, van Leerdam ME, Hol L, Lansdorp-Vogelaar I, Kuipers EJ, van Ballegooijen M.

J Natl Cancer Inst. 2011 Dec 7;103(23):1741-51. doi: 10.1093/jnci/djr385. Epub 2011 Nov 9.

16.

Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening.

Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG, Habbema JD, Kuipers EJ.

J Natl Cancer Inst. 2009 Oct 21;101(20):1412-22. doi: 10.1093/jnci/djp319. Epub 2009 Sep 24.

17.

Which colon cancer screening test? A comparison of costs, effectiveness, and compliance.

Vijan S, Hwang EW, Hofer TP, Hayward RA.

Am J Med. 2001 Dec 1;111(8):593-601.

PMID:
11755501
18.

Cost-effectiveness of screening the average-risk population for colorectal cancer.

Provenzale D.

Gastrointest Endosc Clin N Am. 2002 Jan;12(1):93-109.

PMID:
11916165
19.

Cost-effectiveness of mass screening for colorectal cancer: choice of fecal occult blood test and screening strategy.

Sobhani I, Alzahouri K, Ghout I, Charles DJ, Durand-Zaleski I.

Dis Colon Rectum. 2011 Jul;54(7):876-86. doi: 10.1007/DCR.0b013e31820fd2bc.

PMID:
21654256
20.

Cost-effectiveness analysis on screening for colorectal neoplasm and management of colorectal cancer in Asia.

Tsoi KK, Ng SS, Leung MC, Sung JJ.

Aliment Pharmacol Ther. 2008 Aug 1;28(3):353-63. doi: 10.1111/j.1365-2036.2008.03726.x.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk